Full Press Release Details
Presentation Q 4 2 02 5 1
Disclaimer This presentation of Pelthos Therapeutics Inc. ("we", "us", "our" or the "Company")
contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other
securities laws. Words such as "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "predict, "project,"
"seek," "should," "target," "will," "would" or similar expressions
and the negatives of those term are intended to identify forward-looking statements. Forward-looking statements reflect management's
current expectations, are based on judgments and assumptions, are inherently uncertain and are subject to risks, uncertainties
and other factors, which could cause the Company's actual results, performance or achievements to differ materially from
expected future results, performance or achievements expressed or implied in those forward-looking statements. Examples of these
forward-looking statements and the related risks, uncertainties and other factors include, but are not limited to, the following:
the success of the launch for Zesluvmi, timing, progress and results of any preclinical and clinical trials, its estimates regarding
the potential market opportunity for Zelsuvmi, its ability to develop its pipeline, its ability to protect its intellectual property
and enforce its intellectual property rights, and its ability to execute its development strategy and sustain its competitive
position. Actual future results and trends may differ materially depending on a variety of factors, including, but not limited
to, the Company's limited operating history, the Company's ability to establish its market development capabilities
to commercialize its products and generate any revenue, and the Company's ability to maintain regulatory approval of Zelsuvmi.
Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs
and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Any forward-looking
statement in this presentation, in any related presentation supplement and in any related free writing presentation reflects our
current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to
our business, results of operations, industry and future growth. You should read this presentation with the understanding that
our actual future results may be materially different from any future results expressed or implied by these forward-looking statements.
Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if
new information becomes available in the future. 2
Profile Pelthos Therapeutics is a bio-pharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic
products to help patients with unmet treatment burdens - - - - - Commercial launch of first drug Zelsuvmi,
for the treatment of Molluscum contagiosum ("MC") in July 2025 First and only at home treatment for a large, underserved
market treating contagious viral disease 16.7 million affected people Up to 6 million annual cases in the U.S.
Total addressable market worth in excess of $20 billion at our WAC Experienced management team with over 20 successful
prior drug launches and continued growth, including Cosentyx, Otezla, Ohtuvayre, Xifaxan Upside option on NaV pain programs from
predecessor Current peak Net Revenue forecast of $175M per annum by 2028 and currently meeting or exceeding internal milestones
Key Data Points (as of 10/10/25, except where noted) Ticker PTHS Stock Price $23.26 O/S Shares of Common Stock (on an as converted
basis)* 8.8M Market CAP ~$205M Avg. Daily Trading Volume 31,100 shares (NYSE) Cash at close of merger $27.5M Investment to date
Team Scott Plesha | Chief Executive Officer - >30 years of experience in the pharmaceutical industry, including two decades
building and leading specialty pharma commercial efforts - President and Chief Commercial Officer at BDSI until it was acquired
by Collegium Pharmaceutical in 2022 - Grew BDSI sales from $5 million to $160 million - Previously served as Senior
Vice President of Gastrointestinal Sales at Salix Pharmaceuticals. During fifteen-year tenure at Salix, led nationwide salesforce
that grew product sales to more than $1.5 billion annually - Earned a BA in Pre-Medicine and Pre-Medical Studies at DePauw
University and pursued graduate studies in Dentistry at Indiana University Dental School Frank Knuettel | Chief Financial Officer
- 30 years of management experience in growing early-stage companies - Raised more than $400 million via venture, public
equity and debt offerings and managed more than 15 mergers and acquisition transactions along with large-scale licensing transactions
with fortune 50 companies - Holds numerous board positions, at both public and private companies, including Etheros Pharmaceuticals
- Earned an MBA from The Wharton School and a BA from Tufts University Sai Rangarao | Chief Commercial Officer - -
- - - - >18 years of experience leading, launching, and marketing pharmaceutical products VP of Marketing
& Head of Neurology Sales at Collegium Pharmaceutical VP of Marketing & Commercial Operations at BDSI, until it was acquired
by Collegium in 2022 Head of US Dermatology Marketing for Otezla at Celgene leading to acquisition by Amgen for $13 Billion Member
of the commercial and marketing organization at Novartis Pharmaceuticals that launched COSENTYX in the U.S Earned an MS in
Bioscience Regulatory Affairs from The Johns Hopkins University, an MBA and MS from the New Jersey Institute of Technology, and
a BS in Computer Science from Indiana University of Pennsylvania 4
of Directors Richard Baxter Peter Greenleaf, Chairman Todd Davis Ezra Friedberg Matt Pauls Richard Malamut , MD Scott Plesha 5
Contagiosum A highly infectious viral condition primarily affecting children 1 year of age or older Point prevalence of 3-6 million
children (ages 0-16) in the U.S. Molluscum Contagiosum is caused by a pox virus and is characterized by small, round, firm, umbilicated,
often painless bumps. Even after healing, reinfection is possible if in contact with an infected person or object4. ~17 million
people infected in the U.S. There are four known types of MC virus (MCV1, 2, 3, 4) with MCV1 being the most common1 MC can take
up to five years to resolve without treatment2 Peak incidence between 1-10 years of age. Up to 73% of children go untreated3 Untreated
Molluscum Contagiosum Has Severe Effects Infection, Persistence, and Spread Autoinoculation2 Highly contagious to others Pain
& Skin Irritation risk of secondary bacterial infections2 Potential worsening of atopic dermatitis Itching, redness
Visible and Psychological Impacts Inflammation Anxiety Social withdrawal 1) Hebert AA, Bhatia N, Del Rosso JQ. Mollu scu m Contagiosu
m: Epidemiology, Considerations, Treatment Options, and Therapeutic Gaps. J Clin Aesthet Dermatol. 20 23 Au g;16(8 Su ppl 2):S4-S11.
PMID: 3 7636018; PMCID: PMC10453 394. 2.)Ludmann P. American Academy of Dermatology. Mollu sc um c on tagiosu m. 4 Oc tober 2023
. 3) Basdag H, Rainer BM, Cohen BA. Mollusc um c ontagiosu m: to treat or not to treat? Experience with 170 children in an outpatient
c linic setting in the northeastern United States. Pediatr Dermatol. 20 15;32(3):353-35 7. doi:10.1111/pde.125 04. 4) Sch affer
JV, Berger E M. Mollusc um Contagiosum. JAMA Dermatol. 20 16;152(9):1072. doi:10.1001/jamadermatol.2016.2367. 5) CDC. Clinical
Overview of Mollusc um Contagiosum. Jan 2025 7
Has the Potential to Shift MC Treatment Paradigm Current Options Zelsuvmi - Other available topical treatment requires in-office
visits every 3 weeks2 - Painful, destructive treatments3 - Necessitates travel to HCP offices, adding to the time burden
for MC patients and caregivers2 - Remaining treatment options such as off-label drugs / natural remedies have unproven efficacy4
- Daily application that can be started immediately Breakthrough Product, Breakthrough Results 58.1% Mean MC Lesion reduction
count(1) - Attractive safety profile demonstrated in clinical trials with no / minimal scarring5,6 - First FDA approved
medication for molluscum that can be applied at home by patients or caregivers5 - Demonstrated, proven efficacy across key
primary and secondary endpoints in clinical trials6 1.)Least-squares mean coun t reduction. See Figure 9: Brow nin g JC, Hebert
A, Enloe C, Cartwrigh t M, Maeda-Chub ac hi T. Berdazimer Gel 10.3 % is a Clinically Meaningful Therapeutic Intervention for Mollu
sc um Contagiosu m. Abstract and poster presented at Fall Clinical 2024. Las Vegas, NV. October 24 -27, 2024. 2.) Eichenf ield
LF, Kwong P, Gonzalez ME, et al. Safety and E ffic ac y of VP-10 2 (Cantharidin, 0 .7% w/ v) in Molluscu m Contagiosu m by Body
Region: Post hoc Pooled Analyses from Two Phase III Ran domized Trials. J Clin Aesthet Dermatol. 20 21;14(10):42-47. 3.) Hebert
AA, Bhatia N, Del Rosso JQ. Molluscum Contagiosum: Epidemiology, Considerations, Treatment Options, and Therapeutic Gaps. J Clin
Aesthet Dermatol. 20 23;16(8 Su ppl 1):S4-S11. 4 .) Ong SK, Hoft I, Siegfried E . Analysis of over-the-cou nter products marketed
to treat molluscum con tagiosum. Pediatr Dermatol. 20 21;3 8(5):140 0-14 03. doi:10.1111/pde.14776. 5 .) Zelsuvmi Package Insert.
6.) Su garman JL, Hebert A, Browning JC, et al. Berdazimer gel for mollusc um c ontagiosu m: An integrated an alysis of 3 randomized
controlled trials. J Am Acad Dermatol. 20 24;90(2):299-30 8. doi:10.1016/j.jaad.2023.0 9.066Ong 8
Efficacy Shown in Phase 3 Clinical Trials Drives Commercial Launch Population Intervention Key Study Highlights 808 Males, 790
Females 1,598 participants randomized Patients who applied Zelsuvmi for 12 weeks achieved a mean and median reduction in lesion
count of 58% and 82%, respectively, compared to 36% and 43% for patients who applied a vehicle control gel Mean Lesion Count Reduction(1)
Immunocompetent children and adults aged 6 months with 3-70 raised MC lesions Mean age: 6.7 years (Range: 0.9 - 76.6
years) B-SIMPLE4 Study Locations 55 Clinics across the US 82.4% 58.1% 917 - Zelsuvmi Topical, once-daily application of Zelsuvmi
(berdazimer gel, 10.3%) to all active MC lesions for up to 12 weeks 681 - Vehicle Topical, once-daily application of vehicle control
gel to all active MC lesions for up to 12 weeks Median Lesion Count Reduction(1) 35.7% Zelsuvmi Control 42.6% Zelsuvmi Control
Safety B-SIMPLE4 Primary Outcome - Application site reactions were the most common adverse reaction associated with Zelsuvmi
- Common application site reactions included mild pain and mild erythema (caused by increased blood flow) - Minimal
scarring incidences witnessed 32.4% of patients treated with Zelsuvmi achieved complete clearance of MC lesions at week 12, compared
to 19.7% of patients treated with vehicle control gel in the BSIMPLE-4 pivotal Phase 3 trial 1) p-value <0.000 1, f avoring
Zelsuvmi .. Source: Sugarman JL, Hebert A, Brow nin g JC, Paller AS, Stripling S, Green LJ, Cartwrigh t M, Enloe C, W ells N,
Maeda-Chubac hi T. Berd azimer gel for molluscum contagiosum: An integrated analysis of 3 randomized controlled trials. J Am Acad
Dermatol. 20 23 Oct 5:S0190-9622(23)02890-6. doi: 10.10 16/j.jaad.20 23.09.066.Epub ahead of print. PMID: 37804936. 9
3 Trial Results Zelsuvmi showed statistically significant benefit vs. vehicle after 2 weeks of therapy and through out the entire
12-week length of the Phase 3 studies Least Squares Mean Lesion Reduction(1) Baseline Week 2 0.0% Week 4 Week 8 Week 12 Baseline
Week 2 0.0% -1.1 % -10.7% Median Lesion Reduction(2) Week 8 Week 12 0.0% -9.5% -9.0% Week 4 -10.0% -28.6% -21 .6% -27.8% - 25
.1% -42.6% -35.7% -59.4% -43.5% Zelsuvmi (n= 917) Vehicle (n= 681) - 58 .1% Zelsuvmi (n= 917) Vehicle (n= 681) -82.4% P<0.0001